Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $74.83.
Several equities research analysts recently issued reports on SLNO shares. Stifel Nicolaus boosted their price target on Soleno Therapeutics from $59.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Soleno Therapeutics in a research note on Monday, November 11th. Oppenheimer upped their target price on Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Soleno Therapeutics in a research note on Friday, September 20th.
View Our Latest Report on Soleno Therapeutics
Insiders Place Their Bets
Institutional Trading of Soleno Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank acquired a new stake in Soleno Therapeutics in the second quarter valued at $31,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Soleno Therapeutics in the third quarter valued at $155,000. Curi RMB Capital LLC acquired a new stake in Soleno Therapeutics during the 3rd quarter worth about $202,000. Intech Investment Management LLC acquired a new stake in Soleno Therapeutics during the 3rd quarter worth about $262,000. Finally, Fred Alger Management LLC acquired a new stake in Soleno Therapeutics during the 3rd quarter worth about $310,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.
Soleno Therapeutics Trading Down 1.0 %
Soleno Therapeutics stock opened at $57.22 on Tuesday. Soleno Therapeutics has a 12 month low of $26.38 and a 12 month high of $60.92. The stock’s 50 day moving average is $53.27 and its 200-day moving average is $48.34. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -17.23 and a beta of -1.44.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($1.22). As a group, equities research analysts predict that Soleno Therapeutics will post -3.76 earnings per share for the current fiscal year.
About Soleno Therapeutics
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Featured Stories
- Five stocks we like better than Soleno Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- What is the S&P/TSX Index?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.